Comment on "Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples"
- PMID: 33186336
- DOI: 10.1097/FTD.0000000000000809
Comment on "Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples"
Comment in
-
Comment on "Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples".Ther Drug Monit. 2020 Dec;42(6):910. doi: 10.1097/FTD.0000000000000810. Ther Drug Monit. 2020. PMID: 33197165 No abstract available.
Comment on
-
Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples.Ther Drug Monit. 2020 Feb;42(1):129-132. doi: 10.1097/FTD.0000000000000675. Ther Drug Monit. 2020. PMID: 31318843
References
-
- Al-Shaer MH, Alghamdi WA, Graham E, et al. Meropenem, cefepime, and piperacillin protein binding in patient samples. Ther Drug Monit. 2020;42:129–132.
-
- Schleibinger M, Steinbach CL, Töpper C, et al. Protein binding characteristics and pharmacokinetics of ceftriaxone in ICU patients. Br J Clin Pharmacol. 2015;80:525–533.
-
- Wong G, Briscoe S, Adnan S, et al. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother. 2013;57:6165–6170.
-
- Colman S, Stove V, Waele JD, et al. Measuring unbound versus total piperacillin concentrations in plasma of critically ill patients: methodological issues and relevance. Ther Drug Monit. 2019;41:325–330.
-
- Dorn C, Schießer S, Wulkersdorfer B, et al. Determination of free clindamycin, flucloxacillin or tedizolid in plasma: pay attention to physiological conditions when using ultrafiltration. Biomed Chromatogr. 2020;34:e4820.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
